Pharma outlook 2030: From evolution to revolution

January 7, 2019

The pharmaceutical sector is at a crossroads. In a heavily disrupted marketplace, characterized by shifting payer attitudes and patient empowerment, neither incremental adjustments nor steady evolution are likely to halt the decline of the traditional pharmaceutical business model. This paper looks ahead to a 2030 scenario to examine the trends revolutionizing the sector; trends that we expect to have dramatic impacts.

Spotlight

Aries Pharmaceuticals Inc

Aries Pharmaceuticals Inc. is a wholly owned subsidiary of Aries Pharmaceuticals, Ltd., which is a wholly owned Subsidiary of Cosmo Pharmaceuticals, NV, a specialty pharmaceutical company focused on developing and commercializing best in class products in endoscopy and to treat gastrointestinal diseases. Aries is in charge of the distribution in the US of the Cosmo products.

OTHER WHITEPAPERS
news image

PHARMACEUTICAL KEY ACCOUNT MANAGEMENT: HARNESSING SALES EXPERTISE TO DEVELOP UNIFIED STAKEHOLDER RELATIONSHIPS

whitePaper | November 25, 2022

To meet the needs of a growing range of external stakeholders, many life science companies are changing the ways that they disseminate information.

Read More
news image

The Age of Coaching

whitePaper | March 4, 2022

The pandemic has been healthcare and the pharmaceutical industry’s meteor moment established eco-systems have been wiped out andsales force routines have been scorched from the face of the earth.

Read More
news image

Potential measures to facilitate the productions of activepharmaceutical ingredients (APIs)

whitePaper | March 27, 2023

European countries have been experiencing medicine shortages due to disruptions in the supply chain. Reshoring the productions of active pharmaceutical ingredients (APIs) is considered as an approach to secure the supply.

Read More
news image

Ultrasafe film Ultra-high barrier Product stability Patient safety

whitePaper | December 22, 2022

Every viable pharmaceutical packaging system must comprise materials proven to protect its contents against moisture and other atmospheric variables, and be safe for use with the specified dosage form and the route of administration1

Read More
news image

Understanding the true cost of transparency reporting

whitePaper | December 14, 2022

When the regulatory hammer came down on pharmaceutical and life sciences (PLS) companies in the 2010s, it introduced new complexities for these businesses.

Read More
news image

Securing the modern pharmaceutical supply chain

whitePaper | April 22, 2022

Members of the Health-ISAC community have produced a security framework for the pharmaceutical supply chain comprising this CISO guide.

Read More

Spotlight

Aries Pharmaceuticals Inc

Aries Pharmaceuticals Inc. is a wholly owned subsidiary of Aries Pharmaceuticals, Ltd., which is a wholly owned Subsidiary of Cosmo Pharmaceuticals, NV, a specialty pharmaceutical company focused on developing and commercializing best in class products in endoscopy and to treat gastrointestinal diseases. Aries is in charge of the distribution in the US of the Cosmo products.

Events